

Self · Arcutis Biotherapeutics, Inc. · Arcutis Biotherapeutics, Inc. - Common stock
Purchase
Disclosed range starting at $1K
Disclosed 35 days after execution (STOCK Act deadline: 45)
First recorded trade by this actor in this security
No clustered activity in the dataset
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 0 | Matsuda MasaruEVP, Chief Legal Officer | Option exercise · 10b5-1 plan | M | — 40.0K sh | Nov 4, 2026 traded Nov 4, 2026 | |
| 25 | Matsuda MasaruEVP, Chief Legal Officer | Open-market sale · 10b5-1 plan | SELL | $1.37M 40.0K sh | Nov 4, 2026 traded Nov 4, 2026 | |
| 8 | Matsuda MasaruEVP, Chief Legal Officer | Open-market sale · 10b5-1 plan | SELL | $39K 1,219 sh | Nov 4, 2026 traded Nov 2, 2026 | |
| 3 | Matsuda MasaruEVP, Chief Legal Officer | Option exercise · 10b5-1 plan | M | $146K 40.0K sh | Nov 4, 2026 traded Nov 4, 2026 | |
| 30 | Watanabe ToddDirector, See Remarks | Open-market sale | SELL | $139K 4,377 sh | Nov 4, 2026 traded Nov 2, 2026 | |
| 24 | Burnett PatrickEVP, Chief Medical Officer | Open-market sale | SELL | $30K 943 sh | Nov 4, 2026 traded Nov 2, 2026 | |
| 15 | Scott Robert ADirector | Grant or award | A | — 2,819 sh | Oct 28, 2026 traded Oct 23, 2026 | |
| 15 | Scott Robert ADirector | Grant or award | A | — 8,663 sh | Oct 28, 2026 traded Oct 23, 2026 | |
| 15 | Scott Robert ADirector | Grant or award | A | — 20.5K sh | Oct 28, 2026 traded Oct 23, 2026 | |
| 1 | Matsuda MasaruSee Remarks | Open-market sale · 10b5-1 plan | SELL | $92K 3,674 sh | Sep 18, 2026 traded Sep 16, 2026 | |
| 10 | Matsuda MasaruSee Remarks | Open-market sale · 10b5-1 plan | SELL | $250K 9,989 sh | Sep 10, 2026 traded Sep 8, 2026 | |
| 9 | Curran TerrieDirector | Option exercise | M | — 27.1K sh | Aug 28, 2026 traded Aug 27, 2026 | |
| 20 | Curran TerrieDirector | Option exercise | M | $84K 11.1K sh | Aug 28, 2026 traded Aug 27, 2026 | |
| 24 | Curran TerrieDirector | Option exercise | M | $233K 27.1K sh | Aug 28, 2026 traded Aug 27, 2026 | |
| 44 | Curran TerrieDirector | Open-market sale | SELL | $677K 27.1K sh | Aug 28, 2026 traded Aug 27, 2026 | |
| 9 | Curran TerrieDirector | Option exercise | M | — 11.1K sh | Aug 28, 2026 traded Aug 27, 2026 | |
| 40 | Curran TerrieDirector | Open-market sale | SELL | $279K 11.1K sh | Aug 28, 2026 traded Aug 27, 2026 | |
| 24 | Burnett PatrickSee Remarks | Open-market sale | SELL | $220K 8,300 sh | Aug 13, 2026 traded Aug 11, 2026 | |
| 9 | Burnett PatrickSee Remarks | Option exercise | M | — 8,300 sh | Aug 13, 2026 traded Aug 11, 2026 | |
| 9 | Burnett PatrickSee Remarks | Option exercise | M | $30K 8,300 sh | Aug 13, 2026 traded Aug 11, 2026 |
Read directly from the primary public document; every field below is as reported by the filer.
Midpoint = (low + high) / 2. Used only to rank and sum ranges; the true value can be anywhere in the range.
= $8,001
Gilbert Ray Cisneros, Jr. reported a purchase of Arcutis Biotherapeutics, Inc. - Common stock. Members report a value range, not an exact amount, and do not report share counts or prices. Dates are as entered by the filer. A trade report is not evidence of wrongdoing.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.
Recorded votes from the House Clerk and Voteview (Senate). Listed by date; a vote near a trade is not evidence the two are related.